ERBB2 and cancer: The tremendous success of passive immunotherapy using HER2-targeted mAbs has raised great interest in the search for new B-cell epitopes (the antibody-binding part of the antigen) to be used as targets for anti-HER2 vaccines, especially as the role of vaccination in the management of HER2-positive cancers is expanding [7,125].